Mayo Clinic, BioSig to use AI to improve arrhythmia treatment
Artificial intelligence and machine learning are at the heart of a collaboration between Mayo Clinic and Connecticut-based BioSig Technologies. BioSig, which opened a Rochester office in the Conley-Maass-Downs Building in 2019, recently announced a Mayo Clinic project to enhance Pure EP, its electrophysiological recording system.
Mayo Clinic and Connecticut-based BioSig Technologies , which has an office in Rochester, are deepening their collaboration with an agreement to start a fifth research project involving artificial intelligence.
BioSig, which opened a Rochester office in the Conley-Maass-Downs Building in 2019, recently announced a Mayo Clinic project to use AI and machine learning to enhance Pure EP, its electrophysiological recording system.
“It’s an incredible opportunity,” said BioSig CEO Ken Londoner.
He described the project as another step in BioSig’s growth in Rochester. Looking ahead, as the pandemic is better controlled, Londoner said his company is looking for a larger office space in Rochester. He said the firm has two employees in Rochester and hopes to soon increase that number.
“We plan on being in Rochester for the long run,” he said.
Pure EP is a computerized system for "acquiring, digitizing, amplifying, filtering and much more for patients undergoing electrophysiology procedures" with Mayo Clinic.
BioSig and Mayo Clinic have been working together since 2017, when they signed a 10-year collaboration agreement. The company has licensing and collaboration agreements with Mayo Clinic, which has invested $1 million in Pure EP. BioSig’s subsidiary, NeuroClear Technologies, also works with Mayo Clinic.
In November 2019, BioSig signed three new patent and know-how license agreements with the Mayo Foundation for Medical Education and Research.
When working with patients to treat arrhythmia, Londoner says that “immense amounts of data are generated in real time.” This project will use AI and machine learning to analyze that data and develop further improvements to the system.
The work will be led by Mayo Clinic’s vice chair of innovation Dr. Samuel Asirvatham and Dr. Alexander Wissner-Goss of Reified LLC.
BioSig was also recently working with Mayo Clinic on Vicromax, an antiviral drug to possibly treat COVID-19. Londoner said that project is currently in “limbo.”